XERS Xeris Biopharma Holdings, Inc.

16.62USD-2.18%Mkt Cap: 3.04B USDP/E: —

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-u…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap3.04B USD
Enterprise Value3.20B USD
Revenue (TTM)368.26M USD
Gross Profit249.28M USD
Net Income (TTM)554.00K USD
Revenue/Share2.13 USD
Last Price16.62 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees435
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)62.32
PEG—
EV/EBITDA54.28
EV/Revenue8.69
P/S8.25
P/B62.25
EPS (TTM)-0.03 USD
EPS (Forward)0.27 USD
52W Range
5.25095% of range17.28
52W High17.28 USD
52W Low5.250 USD
Profitability
Gross Margin85.41%
Oper. Margin12.70%
EBITDA Margin16.00%
Profit Margin0.19%
ROE4.05%
ROA0.14%
ROIC15.49%
ROCE9.09%
Growth
Revenue Growth44.20%
Earnings Growth1616.20%
Cash Flow & Leverage
Operating CF28.63M USD
CapEx (TTM)696.00K USD
FCF Margin13.88%
FCF Yield1.68%
Net Debt94.98M USD
Net Debt/EBITDA1.61
Net Debt/FCF1.86
Balance Sheet
Debt/Equity18.85
Current Ratio2.15
Quick Ratio1.49
Book Value/Sh0.27 USD
Cash/Share0.72 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.29 USD
Upside (mean)+4.0%
Target Range12.00 USD – 21.00 USD
12.00+4.0% to mean21.00
# Analysts7
Ownership
Shares Out.182.70M
Float176.52M
Insiders3.00%
Institutions63.92%
Short Interest
Short Ratio3.8d
Short % Float5.08%
Short % Out.4.92%
Shares Short8.99M
Short (prev mo.)7.20M
Technical
SMA 5010.57 (+57.3%)
SMA 2007.877 (+111.0%)
Beta0.84
S&P 52W Chg12.08%
Avg Vol (30d)3.08M
Avg Vol (10d)4.88M
Technical Indicators
RSI (14)80.3
MACD1.8408
MACD Signal1.5721
MACD Hist.+0.2687
BB Upper19.54 USD
BB Middle13.54 USD
BB Lower7.544 USD
BB Width88.58%
ATR (14)0.7041 USD
Vol Ratio (20d)0.75x

About Xeris Biopharma Holdings (NASDAQ: XERS)

›

Xeris Biopharma Holdings (NASDAQ: XERS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 435 employees.

The shares were at 16.62 USD on 19 November 2026, up 68.4% over 52 weeks. Its 52-week range is 5.250 USD to 17.28 USD: the price is 3.8% below the high and 216.6% above the low.

Its market capitalisation is 3.04B USD.

Xeris Biopharma Holdings reports return on equity of 4.0%, an operating margin of 12.7% and revenue up 44.2% year over year.

Its debt exceeds its cash by 94.98M USD, a debt-to-equity ratio of 18.85. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.29 USD is 4.0% above the current price. The next earnings report is expected on 4 March 2027.